Medicamen Biotec

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE646B01010
NSEID: MEDICAMEQ
BSEID: 531146

INR

388.70

-6.4 (-1.62%)

BSENSE

Dec 18

BSE+NSE Vol: 15.3 k

{
  "main_header": {
    "sid": 770569,
    "name": "Medicamen Biotec",
    "stock_name": "Medicamen Biotec",
    "full_name": "Medicamen Biotech Ltd",
    "name_url": "stocks-analysis/medicamen-biotec",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "388.70",
    "chg": -6.4,
    "chgp": "-1.62%",
    "dir": -1,
    "prev_price": "395.10",
    "mcapval": "530.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531146,
    "symbol": "MEDICAMEQ",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE646B01010",
    "curr_date": "Dec 18",
    "curr_time": "",
    "bse_nse_vol": "15.3 k",
    "exc_status": "Active",
    "traded_date": "Dec 18, 2025",
    "traded_date_str": "2025 12 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/medicamen-biotec-770569-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Medicamen Biotec falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-medicamen-biotec-fallingrising-3757747",
        "imagepath": "",
        "date": "2025-12-13 01:04:49",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Gains Defy Broader Market Trends</strong></p>\n<p>Medicamen Biotec’s share price advanced by ₹13.80 on 12 December, marking a 3.53% increase. This rise is particularly significant when viewed against the backdrop of the broader market and sector performance. Over the past week, the stock has gained 5.89%, while the Sensex declined by 0.52%, indicating that Medicamen Biotec has outperformed the benchmark index in the short term. However, the one-month return shows a slight dip of 0.79%, contrasting with the Sensex’s modest gain of 0.95% during the same period.</p>\n<p>The stock’s intraday high reached ₹420.95, a 7.77% increase from its previous close, signalling strong buying interest during the trading session. Moreover, Medicamen Biotec outperformed its sector by 3.48% on the day, ..."
      },
      {
        "title": "Medicamen Biotec Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotec-upgraded-from-strong-sell-to-sell-by-marketsmojo-3738147",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MedicamenBiotec_mojoScore_3738147.png",
        "date": "2025-12-01 10:09:02",
        "description": "Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and valuation considerations that investors should carefully analyse."
      },
      {
        "title": "Medicamen Biotech Reports Strong Profit Growth Amidst Operational Efficiency Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotechs-financial-trend-improves-from-negative-to-positive-amid-strong-profit-growth-3711833",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MedicamenBiotec_fintrenddot_3711833.png",
        "date": "2025-11-18 12:01:23",
        "description": "Medicamen Biotech reported a significant increase in profit after tax for the quarter ending September 2025, reaching Rs 2.67 crore. The company also achieved its highest cash and cash equivalents at Rs 43.68 crore and net sales of Rs 47.17 crore, although it faces challenges with low return on capital employed and debtor turnover."
      },
      {
        "title": "Medicamen Biotech Q2 FY26: Profit Surge Masks Deeper Margin Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/medicamen-biotech-q2-fy26-profit-surge-masks-deeper-margin-concerns-3721211",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/MedicamenBiotec_quaterlyResult_3721211.png",
        "date": "2025-11-18 10:08:09",
        "description": "Medicamen Biotech Ltd., a research-led pharmaceutical company with operations spanning over 40 countries, reported a consolidated net profit of ₹2.67 crores for Q2 FY26, marking an impressive 82.88% year-on-year surge from ₹1.46 crores in the corresponding quarter last year. The sequential improvement was equally robust, with profits climbing 24.19% from ₹2.15 crores in Q1 FY26. However, the stock has struggled to capitalise on this operational momentum, declining 15.50% over the past year whilst the Sensex advanced 9.48%, resulting in a negative alpha of 24.98 percentage points."
      },
      {
        "title": "Is Medicamen Biotec overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-biotec-overvalued-or-undervalued-3706066",
        "imagepath": "",
        "date": "2025-11-17 08:10:16",
        "description": "As of 14 November 2025, Medicamen Biotec's valuation grade has moved from very expensive to expensive, indicating a slight improvement in perceived value. However, the company is still considered overvalued. The key ratios highlight this situation, with a PE ratio of 58.40, an EV to EBITDA of 38.85, and a PEG ratio of 2.88, all of which are significantly higher than industry norms.\n\nIn comparison to its peers, Medicamen Biotec's PE ratio stands out against Sun Pharma's 36.49 and Torrent Pharma's 60.06, while its EV to EBITDA ratio is higher than both Sun Pharma and Cipla, which has an attractive EV to EBITDA of 16.08. The company's recent stock performance has been lackluster, with a year-to-date return of -19.84%, contrasting sharply with the Sensex's gain of 8.22% during the same period, further reinforcing the notion that Medicamen Biotec is overvalued in the current market context...."
      },
      {
        "title": "Is Medicamen Biotec overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-biotec-overvalued-or-undervalued-3705426",
        "imagepath": "",
        "date": "2025-11-16 08:09:52",
        "description": "As of 14 November 2025, Medicamen Biotec's valuation grade has moved from very expensive to expensive, indicating a shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 58.40, an EV to EBITDA of 38.85, and a PEG ratio of 2.88, all of which suggest that the stock is trading at a premium compared to its earnings growth potential.\n\nIn comparison to its peers, Medicamen Biotec's PE ratio significantly exceeds that of Sun Pharma (36.49) and is higher than Torrent Pharma (60.06), both of which are also classified as expensive. Notably, Cipla stands out as attractive with a PE ratio of 22.72, indicating a more favorable valuation in the sector. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -19.84% compared to the Sensex's 8.22%, further reinforcing the notion that Medicamen Biotec is overval..."
      },
      {
        "title": "Is Medicamen Biotec overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-biotec-overvalued-or-undervalued-3704632",
        "imagepath": "",
        "date": "2025-11-15 08:09:58",
        "description": "As of 14 November 2025, Medicamen Biotec's valuation grade has moved from very expensive to expensive, indicating a slight improvement but still reflecting high valuation concerns. The company is currently considered overvalued based on its elevated metrics. Key ratios include a PE ratio of 58.40, an EV to EBITDA of 38.85, and a PEG ratio of 2.88, all of which are significantly higher than industry averages.\n\nIn comparison to its peers, Medicamen Biotec's PE ratio stands out against Sun Pharma's 36.49 and Divi's Lab's 69.65, while its EV to EBITDA ratio is notably higher than Sun Pharma's 24.09 and lower than Divi's Lab's 52.35. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -19.84% compared to the Sensex's 8.22%, further reinforcing the perception of overvaluation...."
      },
      {
        "title": "How has been the historical performance of Medicamen Biotec?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-medicamen-biotec-3703160",
        "imagepath": "",
        "date": "2025-11-14 23:48:32",
        "description": "Answer:\nThe historical performance of Medicamen Biotec shows fluctuations in key financial metrics over the years.\n\nBreakdown:\nMedicamen Biotec's net sales peaked at 179.31 Cr in March 2024 but declined to 162.55 Cr by March 2025. The total operating income followed a similar trend, decreasing from 179.31 Cr in March 2024 to 162.55 Cr in March 2025. The raw material costs also saw a decrease from 104.70 Cr in March 2024 to 90.65 Cr in March 2025, while employee costs increased slightly from 30.07 Cr to 31.87 Cr in the same period. Operating profit (PBDIT) fell from 24.57 Cr in March 2024 to 20.11 Cr in March 2025, reflecting a decline in operating profit margin from 12.4% to 8.53%. Profit before tax decreased from 13.08 Cr to 9.88 Cr, leading to a profit after tax of 6.56 Cr in March 2025, down from 9.49 Cr the previous year. The earnings per share (EPS) also dropped from 8.64 to 5.24. On the balance sheet,..."
      },
      {
        "title": "Is Medicamen Biotec overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-biotec-overvalued-or-undervalued-3700181",
        "imagepath": "",
        "date": "2025-11-14 08:11:06",
        "description": "As of 13 November 2025, the valuation grade for Medicamen Biotec has moved from expensive to very expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 59.70, an EV to EBITDA of 39.67, and a PEG ratio of 2.95, all of which indicate a high valuation relative to earnings and growth potential.\n\nIn comparison to its peers, Medicamen Biotec's PE ratio significantly exceeds that of Sun Pharma (36.15) and is also higher than Torrent Pharma (59.84), both of which are categorized as very expensive. Notably, Cipla, which is rated attractive, has a much lower PE ratio of 22.65, suggesting that Medicamen Biotec's valuation is not justified when compared to more reasonably priced competitors. Additionally, while Medicamen Biotec has seen a strong short-term return of 4.69% over the past week compared to the Sensex's 1.40%, its year-to-date performance is concerning with a decline of..."
      }
    ],
    "total": 6202,
    "sid": "770569",
    "stock_news_url": "https://www.marketsmojo.com/news/medicamen-biotech-770569"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "18-Nov-2025",
      "details": "Announcement under Regulation 30 (LODR) - Newspaper Publication",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For The Quarter And Half Year Ended On September 30 2025",
      "datetime": "14-Nov-2025",
      "details": "Financial Results for the quarter and half year ended on September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Consideration Of Unaudited Consolidated And Standalone Financial Results Of The Company For The Quarter And Half Year Ended On September 30 2025",
      "datetime": "05-Nov-2025",
      "details": "Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve unaudited Financial Results of the Company for the quarter and half year ended on September 30 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Medicamen Biotech Ltd has declared <strong>10%</strong> dividend, ex-date: 19 Sep 25",
          "dt": "2025-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Medicamen Biotec falling/rising?

2025-12-13 01:04:49

Short-Term Gains Defy Broader Market Trends

Medicamen Biotec’s share price advanced by ₹13.80 on 12 December, marking a 3.53% increase. This rise is particularly significant when viewed against the backdrop of the broader market and sector performance. Over the past week, the stock has gained 5.89%, while the Sensex declined by 0.52%, indicating that Medicamen Biotec has outperformed the benchmark index in the short term. However, the one-month return shows a slight dip of 0.79%, contrasting with the Sensex’s modest gain of 0.95% during the same period.

The stock’s intraday high reached ₹420.95, a 7.77% increase from its previous close, signalling strong buying interest during the trading session. Moreover, Medicamen Biotec outperformed its sector by 3.48% on the day, ...

Medicamen Biotec Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-12-01 10:09:02

Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and valuation considerations that investors should carefully analyse.

Medicamen Biotech Reports Strong Profit Growth Amidst Operational Efficiency Challenges

2025-11-18 12:01:23

Medicamen Biotech reported a significant increase in profit after tax for the quarter ending September 2025, reaching Rs 2.67 crore. The company also achieved its highest cash and cash equivalents at Rs 43.68 crore and net sales of Rs 47.17 crore, although it faces challenges with low return on capital employed and debtor turnover.

Medicamen Biotech Q2 FY26: Profit Surge Masks Deeper Margin Concerns

2025-11-18 10:08:09

Medicamen Biotech Ltd., a research-led pharmaceutical company with operations spanning over 40 countries, reported a consolidated net profit of ₹2.67 crores for Q2 FY26, marking an impressive 82.88% year-on-year surge from ₹1.46 crores in the corresponding quarter last year. The sequential improvement was equally robust, with profits climbing 24.19% from ₹2.15 crores in Q1 FY26. However, the stock has struggled to capitalise on this operational momentum, declining 15.50% over the past year whilst the Sensex advanced 9.48%, resulting in a negative alpha of 24.98 percentage points.

Is Medicamen Biotec overvalued or undervalued?

2025-11-17 08:10:16

As of 14 November 2025, Medicamen Biotec's valuation grade has moved from very expensive to expensive, indicating a slight improvement in perceived value. However, the company is still considered overvalued. The key ratios highlight this situation, with a PE ratio of 58.40, an EV to EBITDA of 38.85, and a PEG ratio of 2.88, all of which are significantly higher than industry norms. In comparison to its peers, Medicamen Biotec's PE ratio stands out against Sun Pharma's 36.49 and Torrent Pharma's 60.06, while its EV to EBITDA ratio is higher than both Sun Pharma and Cipla, which has an attractive EV to EBITDA of 16.08. The company's recent stock performance has been lackluster, with a year-to-date return of -19.84%, contrasting sharply with the Sensex's gain of 8.22% during the same period, further reinforcing the notion that Medicamen Biotec is overvalued in the current market context....

Is Medicamen Biotec overvalued or undervalued?

2025-11-16 08:09:52

As of 14 November 2025, Medicamen Biotec's valuation grade has moved from very expensive to expensive, indicating a shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 58.40, an EV to EBITDA of 38.85, and a PEG ratio of 2.88, all of which suggest that the stock is trading at a premium compared to its earnings growth potential. In comparison to its peers, Medicamen Biotec's PE ratio significantly exceeds that of Sun Pharma (36.49) and is higher than Torrent Pharma (60.06), both of which are also classified as expensive. Notably, Cipla stands out as attractive with a PE ratio of 22.72, indicating a more favorable valuation in the sector. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -19.84% compared to the Sensex's 8.22%, further reinforcing the notion that Medicamen Biotec is overval...

Is Medicamen Biotec overvalued or undervalued?

2025-11-15 08:09:58

As of 14 November 2025, Medicamen Biotec's valuation grade has moved from very expensive to expensive, indicating a slight improvement but still reflecting high valuation concerns. The company is currently considered overvalued based on its elevated metrics. Key ratios include a PE ratio of 58.40, an EV to EBITDA of 38.85, and a PEG ratio of 2.88, all of which are significantly higher than industry averages. In comparison to its peers, Medicamen Biotec's PE ratio stands out against Sun Pharma's 36.49 and Divi's Lab's 69.65, while its EV to EBITDA ratio is notably higher than Sun Pharma's 24.09 and lower than Divi's Lab's 52.35. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -19.84% compared to the Sensex's 8.22%, further reinforcing the perception of overvaluation....

How has been the historical performance of Medicamen Biotec?

2025-11-14 23:48:32

Answer: The historical performance of Medicamen Biotec shows fluctuations in key financial metrics over the years. Breakdown: Medicamen Biotec's net sales peaked at 179.31 Cr in March 2024 but declined to 162.55 Cr by March 2025. The total operating income followed a similar trend, decreasing from 179.31 Cr in March 2024 to 162.55 Cr in March 2025. The raw material costs also saw a decrease from 104.70 Cr in March 2024 to 90.65 Cr in March 2025, while employee costs increased slightly from 30.07 Cr to 31.87 Cr in the same period. Operating profit (PBDIT) fell from 24.57 Cr in March 2024 to 20.11 Cr in March 2025, reflecting a decline in operating profit margin from 12.4% to 8.53%. Profit before tax decreased from 13.08 Cr to 9.88 Cr, leading to a profit after tax of 6.56 Cr in March 2025, down from 9.49 Cr the previous year. The earnings per share (EPS) also dropped from 8.64 to 5.24. On the balance sheet,...

Is Medicamen Biotec overvalued or undervalued?

2025-11-14 08:11:06

As of 13 November 2025, the valuation grade for Medicamen Biotec has moved from expensive to very expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 59.70, an EV to EBITDA of 39.67, and a PEG ratio of 2.95, all of which indicate a high valuation relative to earnings and growth potential. In comparison to its peers, Medicamen Biotec's PE ratio significantly exceeds that of Sun Pharma (36.15) and is also higher than Torrent Pharma (59.84), both of which are categorized as very expensive. Notably, Cipla, which is rated attractive, has a much lower PE ratio of 22.65, suggesting that Medicamen Biotec's valuation is not justified when compared to more reasonably priced competitors. Additionally, while Medicamen Biotec has seen a strong short-term return of 4.69% over the past week compared to the Sensex's 1.40%, its year-to-date performance is concerning with a decline of...

View All News

Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication

18-Nov-2025 | Source : BSE

Announcement under Regulation 30 (LODR) - Newspaper Publication

Financial Results For The Quarter And Half Year Ended On September 30 2025

14-Nov-2025 | Source : BSE

Financial Results for the quarter and half year ended on September 30 2025

Board Meeting Intimation for Consideration Of Unaudited Consolidated And Standalone Financial Results Of The Company For The Quarter And Half Year Ended On September 30 2025

05-Nov-2025 | Source : BSE

Medicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve unaudited Financial Results of the Company for the quarter and half year ended on September 30 2025.